Thursday, October 08, 2009
Prosensa, a Centre for Medical Systems Biology (CMSB) spin-off company focusing on RNA modulating therapeutics, announces positive results from its phase I/IIa clinical study on its lead product candidate: the systemic delivery of PRO051 in patients with Duchene muscular dystrophin (DMD) was well tolerated and induced novel expression of dystrophic.
Read more